Wednesday, March 1, 2017
Illumina's GRAIL Raises $900M In Funding Round
GRAIL, the cancer detection spinout of San Diego's Illumina, said this morning that it has raised $900M in a first close of a planned, $1 billion funding round. The Series B funding was led by Arch Venture Partners, and included Johnson and Johnson Innovation, Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. Illumina spun out GRAIL last year. GRAIL is based in Silicon Valley.